For systemic therapy, two out of seven KPIs met target standards: proportion of patients with endocrine-sensitive invasive cancer who received endocrine therapy—97.4% (95% CI 95–100%)—and proportion of patients with HER2-positive invasive carcinoma (T > 1 cm or node-positive) treated with chemotherapy who received adjuvant trastuzumab—92% (95% CI 81–103%). Here, ERBB2 is linked to invasive carcinoma.